Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Enanta Pharmaceuticals Inc
ENTA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$11.31
-0.36
-3.08%
Ult. Agg.: Oct 21, 4:00 PM
$11.31
-0.36
-3.08%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Enanta Pharma Financials
Enanta Pharma (ENTA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent. This is a 21.18 percent increase over losses of $(0.85) per share from
Benzinga Newsdesk
PRO
Enanta Pharma Q2 EPS $(0.45) Beats $(0.49) Estimate, Sales $17.159M Beat $17.092M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.49) by 8.16 percent. This is a 57.55 percent increase over losses of $(1.06) per share from the
Benzinga Newsdesk
Enanta Pharma Earnings Review: Q1 Summary
Benzinga Insights
PRO
Enanta Pharma Q1 EPS $(0.42) Beats $(0.81) Estimate, Sales $18.615M Beat $16.140M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.81) by 47.96 percent. This is a 60 percent increase over losses of $(1.05) per share from the
Benzinga Newsdesk
Earnings Scheduled For February 9, 2026
Benzinga Insights
Earnings Preview For Enanta Pharma
Benzinga Insights
